TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03836209
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles
Study: NCT02357407
Drug: Patients in intensive care : infection treated with ciprofloxacin IV
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-10 samples per patients on day-4 of their treatment
Study: NCT02357407
Drug: Osteoarticular infected patients : infection treated with oral ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-10 samples per patients on day-4 of their treatment
Study: NCT02945020
Drug: Dabigatran etexilate mesylate
Normalized name: Dabigatran Etexilate Mesylate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive dabigatran etexilate mesylate 75 mg, orally.
Study: NCT02945020
Drug: Odalasvir (ODV)
Normalized name: ODV
DrugBank: Odalasvir (DB13041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ODV 25 mg, orally.
Study: NCT02945020
Drug: Simeprevir (SMV)
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive SMV 75 mg, orally.
Study: NCT04391556
Drug: Firmagon
Normalized name: Firmagon
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
Study: NCT03594422
Drug: HQP1351
Normalized name: HQP1351
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
Study: NCT00005893
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005893
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03800134
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Study: NCT03800134
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Study: NCT03800134
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Study: NCT03800134
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study: NCT03800134
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study: NCT03800134
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Study: NCT02121405
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
Study: NCT02729467
Drug: JNJ-53718678
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
Study: NCT02729467
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
Study: NCT02729467
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
Study: NCT02816021
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
Study: NCT02816021
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
Study: NCT02123758
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study: NCT02123758
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study: NCT02123758
Drug: JNJ-56021927
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Study: NCT03623321
Drug: Pimavanserin
Normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
Study: NCT01349959
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01349959
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02394197
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study: NCT02394197
Drug: primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study: NCT00117533
Drug: pegylated IFN alfa-2b plus ribavirin
Normalized name: Interferon Alfa-2B
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02311101
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravesically
Study: NCT03915860
Drug: Trifarotene
Normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Cream
Study: NCT03210688
Drug: Alfacalcidol
Normalized name: Alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule alfacalcidol 0,5 microgram/day
Study: NCT03422796
Drug: Cilostazol 200mg
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT03422796
Drug: SUMAtriptan 6 MG/ML
Normalized name: sumatriptan 6 MG/ML
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT00437437
Drug: Brivanib
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
Study: NCT04529096
Drug: LY3016859
Normalized name: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01552005
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Intervention
Study: NCT00401024
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01079702
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
Study: NCT01710371
Drug: 18F-AV-133
Normalized name: 18F-AV-133
DrugBank: Florbenazine F-18 (DB14945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 296 MBq (8 mCi)
Study: NCT03774498
Drug: Sensodyne repair and protect
Normalized name: Sensodyne Repair and Protect Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NovaMin \& fluoride toothpaste
Study: NCT00627445
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
Study: NCT00627445
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, 500 - 2000 mg, once, twice or three times daily
Study: NCT00627445
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
Study: NCT06400225
Drug: Ulixertinib
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01316107
Drug: ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT01316107
Drug: nateglinide
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02217527
Drug: Active JNJ Drug
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
Study: NCT01722227
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01946906
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03634540
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan tablets administered orally.
Study: NCT03634540
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablets administered orally.
Study: NCT01039584
Drug: Butoconazole Nitrate Vaginal Cream
Normalized name: Butoconazole Nitrate Vaginal Cream
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vaginal cream
Study: NCT01215864
Drug: TCD-717
Normalized name: TCDO
DrugBank: Tetrachlorodecaoxide (DB05389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2
Study: NCT00659477
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily
Study: NCT00319319
Drug: Mecamylamine hydrochloride (Inversine)
Normalized name: mecamylamine hydrochloride Oral Tablet [Inversine]
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00081861
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg given intravenously every 2 weeks for 4 doses.
Study: NCT00081861
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
Study: NCT04241068
Drug: Aducanumab
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04538742
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DXd: administered as an IV infusion
Study: NCT03843151
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of single dose of 10 milligram (mg) BI 1358894 (2 tablets of 5 mg) with 240 milliliter (mL) of water after an high-fat, high-calorie breakfast on Day 1 of Treatment Period 1.
Study: NCT03843151
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 200 mg itraconazole (20 mL of 10 mg/mL solution) with 240 mL of water after an overnight fast for at least 10 h once daily for 14 days on Days -3 to 11 combined with a single dose of 10 mg BI 1358894 (2 tablets of 5 mg) on Day 1 of Treatment Period 2, 1.5 hours after administration of itraconazole.
Study: NCT04266301
Drug: Sabatolimab
Normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
Study: NCT04266301
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
Study: NCT00659581
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04078659
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
Study: NCT04078659
Drug: Magnesium Sulfate infusion
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
Study: NCT00268385
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00268385
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03317158
Drug: Durvalumab (Cohort 1-3)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
Study: NCT04538742
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab: administered as an IV infusion
Study: NCT03317158
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
Study: NCT03317158
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
Study: NCT03317158
Drug: Durvalumab (Cohort 4/5)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
Study: NCT02582684
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants were prescribed 50 mg of DTG orally daily
Study: NCT04078659
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
Study: NCT02582684
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants were prescribed 300 mg of 3TC orally daily.
Study: NCT04538742
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: administered as an IV infusion
Study: NCT04078659
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive propofol in a dose of 1-2 mg /kg
Study: NCT04078659
Drug: Atracurium
Normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
Study: NCT02171559
Drug: Enoxaparin prefilled syringes
Normalized name: enoxaparin Prefilled Syringe
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02171559
Drug: Dabigatran etexilate capsules
Normalized name: Dabigatran Etexilate Capsules
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04538742
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab: administered as an IV infusion
Study: NCT05391893
Drug: Oral
Normalized name: Doral
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
Study: NCT04538742
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib administered orally (tablet) twice daily
Study: NCT00000135
Drug: MSL-109
Normalized name: SDZ-MSL-109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
Study: NCT02971501
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03169790
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03169790
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study: NCT03169790
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-acid ethyl esters
Study: NCT03169790
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study: NCT03169790
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
Study: NCT01994239
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
Study: NCT00967785
Drug: Mozobil (TM)
Normalized name: Mozobil
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily subcutaneous injection or via continuous subcutaneous infusion
Study: NCT03332940
Drug: Tc 99M Sulfur Colloid
Normalized name: Technetium Tc 99m sulfur colloid
DrugBank: Technetium Tc-99m sulfur colloid (DB09397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
Study: NCT03332940
Drug: Tc99m-tilmanocept
Normalized name: technetium (99mTc) tilmanocept
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT02078973
Drug: 15 mg tolvaptan
Normalized name: tolvaptan 15 MG
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg pr day for 1 day
Study: NCT02078973
Drug: 30 mg tolvaptan
Normalized name: tolvaptan 30 MG
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg pr day for 1 day
Study: NCT02078973
Drug: 45 mg tolvaptan
Normalized name: tolvaptan 45 MG
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg pr day for 1 day
Study: NCT00327808
Drug: TPI-1020
Normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
Study: NCT00327808
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mcg BID x 14 days then 800 mcg/day x 7 more days
Study: NCT03563235
Drug: Xulin Jiangu granules
Normalized name: Jiang Huang (Curcuma Longa)
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xulin Jiangu granules tablets
Study: NCT03563235
Drug: Calcitriol capsules
Normalized name: Calcitriol Capsules
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol capsules tablets
Study: NCT04245397
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
Study: NCT04245397
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine is a hypomethylating agent.